United States Patent 9,012,440: Scope, Claim Construction, and US Patent Landscape for (rac)-Tramadol HCl–Celecoxib Co-Crystals
United States Patent 9,012,440 claims a specific co-crystal system of (rac)-tramadol hydrochloride and celecoxib, constrained by a 1:1 molecular ratio and characterized by three objective solid-state features: (i) a DSC endothermic sharp melting peak onset at 164°C, (ii) a defined FTIR absorption band set, and (iii) an orthorhombic unit cell with specified lattice parameters. Downstream claims cover pharmaceutical compositions containing the co-crystal in physiologically acceptable media. This is a classic “defined crystalline form” estate: novelty and enforceability typically hinge on whether an accused co-crystal matches all key structural/analytical characteristics, not on generic co-administration or mere physical mixing.
What is US Patent 9,012,440 claim scope for (rac)-tramadol HCl and celecoxib co-crystals?
Core invention (claims 1–3): a crystalline co-crystal with exact identity and testable solid-state signatures.
What does claim 1 cover (molecular ratio + DSC onset threshold)?
Claim 1 requires all of the following:
- Co-crystal identity: (rac)-tramadol.HCl and celecoxib co-crystal (not salt alone, not eutectic alone, not simple physical mixture).
- Molecular ratio: 1:1 (tramadol HCl : celecoxib).
- Thermal signature: “endothermic sharp peak corresponding to melting point” has onset at 164°C (as written; practically this becomes an infringement focus for DSC method, heating rate, sample history, and baseline integration).
Practical claim construction points
- “Onset at 164°C” is a hard numerical anchor. In litigation, this tends to become a contest over whether the onset is measured at 164°C within the patent’s effective tolerance under the accused product’s DSC conditions.
- “Endothermic sharp peak corresponding to the melting point” is also method-sensitive. Courts often treat analytical endpoints as intrinsic to the claimed form, but the measurement protocol can decide whether the accused material is “the same.”
Does claim 2 broaden or narrow claim 1?
Claim 2 depends on claim 1 and adds FTIR pattern requirements, namely absorption bands at listed wavenumbers (with varying intensity markers like “(s)” and “(m)”).
Because claim 2 depends on claim 1, infringement requires:
- the claim 1 co-crystal definition, plus
- the claim 2 FTIR band set.
Implication: claim 2 is narrower than claim 1 because it adds additional analytical constraints. In dispute, a defendant could argue their product lacks one or more required bands or has shifted band positions attributable to different crystalline form, hydration, disorder, or processing.
Does claim 3 define a specific polymorph/unit cell?
Claim 3 depends on claim 1 and requires an orthorhombic unit cell with:
- a = 11.0323(7) Å
- b = 18.1095(12) Å
- c = 17.3206(12) Å
Implication: this is the tightest identity test. Unit cell parameters are typically derived from X-ray diffraction (single crystal or powder Rietveld refinement). That makes claim 3 a strong discriminator against:
- other crystalline co-crystals,
- amorphous material,
- hydrate/solvate variants,
- different stoichiometries,
- polymorphic analogs with the same components but different lattice constants.
How do claims 4–6 expand into pharmaceutical composition coverage?
Claims 4–6 are composition claims covering “a pharmaceutical composition comprising a therapeutically effective amount” of the co-crystal in a physiologically acceptable medium.
- Claim 4: composition containing the claim 1 co-crystal (DSC-onset-defined).
- Claim 5: composition containing the claim 2 co-crystal (DSC + FTIR band-defined).
- Claim 6: composition containing the claim 3 co-crystal (DSC + FTIR + unit cell, via dependency chain).
Scope characteristics
- These claims generally do not specify dosage form (tablet, capsule, granule), route, or excipients beyond “physiologically acceptable medium.”
- They do not appear to limit release profile or manufacturing process.
- Therefore, the limiting factor becomes whether the active solid form in the finished dosage corresponds to the claimed co-crystal.
What patents does US 9,012,440 likely relate to in the tramadol HCl–celecoxib combination and solid-form space?
Based on claim content alone, US 9,012,440 fits a broader solid-state strategy in combination analgesics: define a crystalline co-crystal to improve properties (often solubility, dissolution rate, bioavailability, or stability) relative to components or simple blends.
Landscape framing (what typically exists around this kind of estate)
In practice, the adjacent patent bundles for such systems commonly include:
-
Co-crystal formation patents
- stoichiometries other than 1:1
- different polymorphs / orthorhombic vs other space groups
- different preparation methods (solvent, cooling, evaporation)
-
Solid form characterization patents
- different XRD fingerprints
- different DSC/FTIR tolerance ranges
- stability under humidity/temperature
-
Pharmaceutical formulation patents
- tablet/capsule compositions
- disintegrants, binders, lubricants
- processing conditions and particle size thresholds
-
Combination therapy / method-of-use patents
- co-administration or synergistic dosing regimens of tramadol and celecoxib
- analgesic treatment claims
Enforceability focus: if an asserted competitor uses a different co-crystal form (different stoichiometry, or different unit cell), they can often avoid identity-based crystalline claims unless those other forms are also claimed in a dependent or separate patent family.
How strong is the patent estate for crystalline identity under claim 1 vs claim 3?
Claim 1 (DSC onset at 164°C) strength profile
- Strength: numerical thermal endpoint can be enforceable if the defendant’s product matches the specific co-crystal and the measurement method is consistent.
- Risk factors: DSC onset values can shift with experimental parameters, sample purity, heating rate, and thermal history. That variability can widen practical litigation uncertainty.
Claim 3 (orthorhombic unit cell constants) strength profile
- Strength: unit cell parameters are typically harder for competitors to “accidentally” hit unless they truly made the same crystalline structure.
- Risk factors: XRD data can depend on refinement model, instrument calibration, preferred orientation, crystallite size, and whether the sample contains minor impurities or polymorphic mixture.
Net: claim 3 typically provides the strongest “form identity” lock; claim 1 provides the most general thermal gateway; claim 2 provides an additional orthogonal fingerprint.
What is the likely infringement analysis for a product with tramadol HCl and celecoxib co-crystal?
A competent infringement test for these claims generally proceeds as follows:
- Confirm active solid form is a co-crystal (not mixture, not salt-only, not eutectic).
- Determine stoichiometry: 1:1 molecular ratio.
- Run DSC and confirm onset of the endothermic sharp melting peak at 164°C.
- Run FTIR and confirm presence of required absorption bands at the specified wavenumbers with matching intensity assignments.
- Run XRD and confirm orthorhombic unit cell parameters a, b, c within the claimed tolerances.
Design-around pathways
- Use a different stoichiometry (2:1, 1:2, etc.) if other co-crystals are available outside the claim.
- Use a different polymorph (different space group/unit cell) while keeping the same components.
- Use amorphous dispersion or a different crystalline form plus formulation strategies, avoiding the claimed unit cell/FTIR/DSC combination.
- Maintain 1:1 but alter solid state enough that DSC onset shifts away from 164°C or FTIR bands deviate.
What generic or competitor entry risks exist for products aimed at tramadol–celecoxib co-crystal differentiation?
The biggest risk vector is not “generic entry” in the usual small-molecule formulation sense; it is crystalline form freedom-to-operate. If a competitor markets an NDA/ANDA-like product containing the same co-crystal form, they face direct infringement of identity-defined claims.
Key commercial risk: co-crystal patents often block not only the drug product’s final dosage but also intermediate manufacture, because co-crystal formation is typically tied to the active solid form used throughout manufacturing.
Typical competitor strategies
- Switch to physical mixture plus formulation work to achieve dissolution gains.
- Move to a different co-crystal form or polymorph.
- License a form-specific portfolio if manufacturing scale-up requires the claimed crystal.
What does the claimed IR band list suggest about what competitors must match?
Claim 2’s FTIR requirement is specific: it lists numerous absorption bands across the mid-IR region (notably including bands in the 1100–1300 cm−1 range and around ~1168.7 cm−1 listed twice with “(s)”). This implies the inventors expect a reproducible spectral pattern tied to the lattice interactions between tramadol HCl and celecoxib.
For infringement, the defendant typically must show their material’s FTIR:
- includes these bands,
- with appropriate peak positions (wavenumber alignment),
- and compatible intensity classification.
Design-around: even if components are the same and stoichiometry is 1:1, altering crystallinity, hydration level, disorder, or making a different polymorph can shift and/or split bands, potentially avoiding the claim.
How does the orthorhombic unit cell constraint affect patent blocking power?
Claim 3 narrows to a specific orthorhombic structure with precise dimensions. This increases blocking power against:
- “same co-crystal concept” marketing where the company uses a different unit cell refinement,
- batches with mixed polymorphs (depending on how purity/phase mixture is treated in infringement),
- solid-form variants, including solvate/hydrate forms if they alter lattice constants.
In licensing talks, the unit cell requirement often becomes the key diligence test: parties will want XRD confirmation that the manufactured crystal aligns with the claimed lattice.
What is the regulatory relevance for solid-form patents in the US?
Even without the drug’s FDA submission details, the legal/regulatory link for a crystalline form patent is consistent:
- If a sponsor files to use a specific solid form, the NDA/ANDA chemistry manufacturing controls and characterization packages often document DSC/FTIR/XRD.
- Patent assertions can attach to those marketed and manufactured solids, independent of dosage form excipients.
Implication for Paragraph IV and patent challenges: if any Orange Book-listed patents cover the active solid form, a generic developer typically evaluates whether it can launch a product without infringing those form-specific claims by using a different solid form or by showing non-infringement/invalidity.
What is the Orange Book status of US 9,012,440 and which companies may be affected?
No answer can be produced here from the provided information. The patent’s Orange Book listing status requires the patent-to-NDA/ANDA mapping, which is not supplied.
Timeline: when could US 9,012,440 expire, and when would exclusivity end?
No answer can be produced here. Expiration dates depend on the patent’s filing date, any PTA, and continuation/prosecution history. The prompt provides claims only, not bibliographic data.
Key takeaways
- US 9,012,440 is a crystalline co-crystal patent for (rac)-tramadol.HCl–celecoxib with a strict 1:1 ratio.
- The claim set is defined by objective solid-state characterization:
- DSC melting onset at 164°C (claim 1),
- specific FTIR bands (claim 2),
- orthorhombic unit cell parameters (claim 3).
- Composition claims (4–6) extend protection to finished pharmaceutical products containing the claimed co-crystal in physiologically acceptable media.
- For competitors, the primary entry risk is solid-form identity. Design-around typically requires switching stoichiometry, polymorph/unit cell, or crystal form enough that DSC/FTIR/XRD no longer match the claimed thresholds.
FAQs
- Does a physical mixture of (rac)-tramadol HCl and celecoxib infringe US 9,012,440?
- Can a competitor avoid infringement by using the same components but a different co-crystal stoichiometry than 1:1?
- What DSC factors most often shift melting peak onset values in co-crystal disputes?
- If a material is a polymorphic mixture, does it still meet the orthorhombic unit cell limitation in claim 3?
- How do FTIR peak position and intensity assignment typically affect non-infringement arguments for claim 2?
References
No sources were provided in the prompt, and no bibliographic or Orange Book mapping data was included.
